Clinical trials: GERD With Erosive Esophagitis
Erosive Esophagitis
Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities.
- Trial name
- INVEST (NCT06720610)
- Testing
- Vonoprazan 20 mg, Esomeprazole
- Where
- 5 sites in Indonesia
- Volunteers
- 216 people
- Sponsor
- Universitas Indonesia
Healthy Volunteers
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and…
- Trial name
- NCT06831344
- Testing
- Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease With Esophagitis
PPI Dosing Per CYP2C19 Genotype
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication…
- Trial name
- NCT07843264
- Testing
- CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Florida
Gastroesophageal Reflux, Esophagitis
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
- Trial name
- NCT00195208
- Testing
- Pantoprazole for approximately 9 weeks
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gut-Brain Disorders, GERD Without Erosive Esophagitis
Cognitive-behavioral Therapy for the Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
Gastroesophageal reflux disease (GERD) is a challenging gastrointestinal disorder, and proton pump inhibitors (PPIs) are typically the first line of treatment.
- Trial name
- NCT06939465
- Testing
- Cognitive Behavioral Therapy (CBT)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Hualien Tzu Chi General Hospital
Gastroesophageal Reflux Disease (GERD), Heartburn
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Trial name
- NCT01129713
- Testing
- Secretol, Nexium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Effexus Pharmaceutical
Erosive Esophagitis, Reflux Esophagitis
Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis
This study is being done to for two reasons: To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly.
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, GERD
- Trial name
- EE (NCT00586963)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Erosive Esophagitis, GERD
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.
- Trial name
- NCT02028663
- Testing
- CJ-12420, Esomeprazole
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- HK inno.N Corporation
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole…
- Trial name
- NCT07313774
- Testing
- Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose
- Sponsor
- Cinclus Pharma Holding AB
GERD
High Definition Endoscopy With NBI. Contribution in Patients With Non-erosive Esophagitis
Most patients with symptomatic gastroesophageal reflux disease (GERD) have a normal upper gastrointestinal endoscopy. Attempts have been made to define new endoscopic techniques for identification of abnormalities non detected in…
- Trial name
- NCT03824431
- Testing
- Endoscopic esophageal biopsies
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Gastro-esophageal Reflux Disease
Epithelial Damage in GERD
The purpose of this study is to characterize and compare epithelial damage in patients with erosive esophagitis and non-erosive reflux disease.
- Trial name
- NCT01867931
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center